Medicus Pharma Ltd. has announced a definitive agreement to acquire Antev Ltd., a UK-based clinical-stage drug development company. Under the terms of the agreement, Medicus will acquire all issued and outstanding shares of Antev in exchange for approximately 17% of Medicus's common shares. Antev shareholders are also eligible to receive up to $65 million in additional contingent payments, dependent on future FDA Phase 2 and New Drug Application approvals. The transaction is anticipated to close by the end of August 2025, pending the fulfillment of closing conditions, including Antev shareholder approval. Antev is currently focused on developing Teverelix, a GnRH antagonist, for treating cardiovascular high-risk prostate cancer and acute urinary retention.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。